Thank you, Bob, and good morning, everyone.
Across been of evaluating and I and participating non-small Summit which made year III are Akeso our Ivonescimab over treated just in potential. enthusiastic XX with cancer. X cell of the trials evaluating with have tumor now X conducting discussed, about Bob beyond its As patients incredibly X,XXX is have accomplishments or partnership Currently, Team solid lung we Ivonescimab, remain are and the Ivonescimab The Akeso. X into globe, Ivonescimab. Phase in in clinical settings strength trials
are and multiple Europe our a licensed U.S., across Ivonescimab the We including strong partnership in territories, ongoing clinical Akeso, in with leverage tumor such Canada, and solid data have Japan. collaboration fortunate to own ability support of the Summit's development generated for to studies
Turning specifically Active trials. enrollment in HARMONi HARMONi-X. Phase and to own continues Summit's III
EGFR as patients HARMONi, half intend progressed a our XXXX. lung enrollment in complete the to mutations Osimertinib. non-small is trial in We reminder, As of following third-generation in fast-to-market a this have with who cell second approach cancer TKI, such
trial for standard head-to-head Our the cancer. plus Ivonescimab lung frontline non-small designed with plus HARMONi-X This current chemotherapy. compare seeking squamous Pembrolizumab patients trial indication care is is a against to of chemotherapy treatment cell
We achieve progress, patients lung options with many goals as treatment to collapse improve the ultimately ongoing time, our Ivonescimab to serious as for order unmet aggressive continue cancer to existing realistic to well needs. but in
our II of with pursue This data median in multiple genomic part supporting decision in follow-up data Our conducted rate reached X in XX come months. non-small following positive observed. study acceptable trial to of HARMONi XX.X% generated progressed our lung directly metastatic considering belief this Furthermore, survival Median from safety the Phase advanced this chemotherapy III from settings, with an for current our by trials. cell clinical a both by Akeso. Akeso Phase in when was patient actionable a profile cancer conviction had registrational EGFR II or without lung clinical evaluating Ivonescimab III move overall AKXXX-XXX having Phase after first-line We observed. that trial, and Phase survival Also, Ivonescimab, XX-month in in our trials last of yet and forward survival a in In was cell is patients promising. trial. very month. cohort EGFR clinical of with our supporting decision data not the standard tumors Phase median in TKI, care time cancer XX.X a squamous II II metastatic the settings, supports been Notably, was population, the believe plus overall trial, overall advanced quickly II an mutations patients Phase the of lung has cancer updated potential or data Ivonescimab alterations non-small population HARMONi-X has and has trials, and months of to Phase both in
X, drug in to less we What affinity differentiates the like are is concept intentional VEGF the together and more targeting XX-fold. qualities binding to the VEGF to presence its in clinically in its of the U.S., toward PD-X, the tumor only in And tumor, PD-X Ivonescimab. cooperative please. of presence higher the X binding, action Slide fourfold. increases kind a everyone cooperative as tiered earlier, Phase also we molecule both to of Ivonescimab the design advanced most Bob believe, VEGF. differentiated binding PD-X novel Japan. bispecific area is the lead making vitro PD-X VEGF of our by PD-X oncology to specifically the brings comparatively and compound normal it Canada, environment, mentioned Ivonescimab as and over validated of potential Ivonescimab's known into expressed of the licensed spend territories, healthy III In a VEGF, will I Europe and to in and are mechanists To mechanism remind drug, tissues. X Ivonescimab levels in tumor-marker moment highly steer of the increases of where around start, by
opportunity and avidity. a increased can tumor in not increased VEGF presence the believe Ivonescimab you tumor of administration binding compounds also than We as goes the an anti-VEGF further as X, Ivonescimab bind PD-X Because is is well. multiple Slide cooperative sequential dimers because therapy. addition, microenvironment dimer, there and in VEGF there to of only these of see, anti-PD-X but affinity the to in increase the expressed an VEGF On microenvironment,
targets. FX the improve We to profile upon previously is has believe established goal X these safety Our with standards Ivonescimab to achieve addition associated this. in to potential efficacy and site
Slide to X. Moving
for multiple are we at Ivonescimab, in near-term Looking occur events XXXX. to meaningful catalysts expecting
to AKXXX-XXX, the partners from a in at the expected population are CDE. authority, treat this expected study, submitted quarter, A of multiregional to randomized the Chinese modified approval from from patients is milestones portion enrolled year, in last the was our Chinese included Chinese in X the from in there known HARMONi which Phase China of Next year quarter regulatory China. the intent Data the patients of Akeso. seeking also in marketing specifically our represent III decision clinical large CDE trials second as key
top that results III a of expect readout this Akeso of Phase the the also trial data line will at We provide time.
major tumors to a both planned milestone AKXXX-XXX. setting Ivonescimab action PD-X in in from has comparing advanced novel as with antibody of as of does expression not differentiating PD-LX next lung mechanism quarter for This Pembrolizumab is monotherapy for for a therapeutics Akeso exist analysis in first-line for referred today. an harboring its study illustrating against Ivonescimab, a trial patients as simply Additionally, potential the Pembrolizumab interim Ivonescimab well oncology that head-to-head to its cancer positive
as event the Ivonescimab's direct drivers study the be pivotal in globally. HARMONi potential we well development our on ability AKXXX-XXX, results believe Ivonescimab/Pembrolizumab of in to the moment this Given compare AKXXX-XXX implications will as
plan providing territories. towards of study Ivonescimab mentioned half second for we As in licensed this in our also enrollment year, submission in the a to complete earlier, the HARMONi momentum
and for cell additional step While believe our cancer in non-small indications non-small expand represents we HARMONi plan our the will our indication to represents and in lung initial development strategy, clinical program. first Ivonescimab, potential lung has cancer solid and other cell we in Ivonescimab tumors. HARMONi-X continue both
outside In progressing other of appreciate in significant leaders development are for we and Ivonescimab from do a a leaders to key and lung our we physician difference opinion of positive internal cancer. program, level to hearing addition high can make what enthusiasts
considering to receive programs. multiple or for IST investigator-sponsored potential inquiries are continue and trials We
to later in expect information share XXXX. We additional
reach leaders and upcoming cancer to local community and Finally, academic with to few KOLs participating physicians, capitalize many we a so conferences. physicians are caregivers, seeing from in and on expand our patients,
We later Santa Lung Cancer, meeting at IASLC be will California. this Therapies TTLC, week Monica, in or Targeted for
on presentation we we our to in ask for possible that and month along and partners plan next activate ramp physicians I as participate the Ivonescimab. in Congress, regarding XXXX many Akeso Europe, educate intend United clinical where Japan. to financial addition, details trials potential III Cancer Ivonescimab update, and European our We with Prague, as will With now as Lung and submitted to multiple In Ankur its at we in ESMO, have position up Canada Phase provide on outlook. abstract States,
